Shopping Cart 0
Cart Subtotal
USD 0

Artios Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Artios Pharma Ltd (Artios Pharma) is an independent company that focuses on the development of DNA Damage Response (DDR) therapies to treat cancer. The company has in-licensed its lead DDR programme, DNA polymerase theta (PolO) from Cancer Research Technology (CRT), which target proteins that control major aspects of DNA repair and other cellular processes. It is also developing novel cancer treatments targeting DNA nucleases involved in the DDR in partnership with Masaryk University. The company is funded by SV Health Investors, Touchstone Innovations, Merck Ventures, CRT Pioneer Fund (managed by Sixth Element Capital), Arix Bioscience plc, and AbbVie Ventures. Artios Pharma is headquartered in Cambridge, England, the UK.

Artios Pharma Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Artios Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 10

Artios Pharma Raises USD33.2 Million in Series A Financing 12

Partnerships 14

Artios Pharma Enters into Research Agreement with Masaryk University 14

Artios Pharma Research Agreement with Cancer Research Technology 15

Licensing Agreements 16

Artios Pharma Exercises Option for Licensing Agreement with Masaryk University 16

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 17

Artios Pharma Ltd-Key Competitors 18

Artios Pharma Ltd-Key Employees 19

Artios Pharma Ltd-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Corporate Communications 21

Sep 04, 2017: Arix Bioscience notes the appointment of Dr Graeme Smith as CSO of Artios Pharma 21

Jun 08, 2017: Artios announces formation of world-leading Scientific Advisory Board 22

Jun 08, 2017: Arix Bioscience notes the formation of Artios Pharma's world-leading Scientific Advisory Board 24

Appendix 26

Methodology 26

About GlobalData 26

Contact Us 26

Disclaimer 26


List Of Figure

List of Figures

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Artios Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Artios Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Artios Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Artios Pharma Raises USD83.6 Million in Series B Venture Financing 10

Artios Pharma Raises USD33.2 Million in Series A Financing 12

Artios Pharma Enters into Research Agreement with Masaryk University 14

Artios Pharma Research Agreement with Cancer Research Technology 15

Artios Pharma Exercises Option for Licensing Agreement with Masaryk University 16

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 17

Artios Pharma Ltd, Key Competitors 18

Artios Pharma Ltd, Key Employees 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Artios Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.